Collaboration will enable at-home & point-of-care serum collection without phlebotomyContinue reading
Category Archives: AZBio News
An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences: October 8, 2020
Daniel O’Day – October 08, 2020
With today’s publication of new data on remdesivir in the New England Journal of Medicine, we have the clearest picture yet of the medicine’s impact on COVID-19. Over the past months, we had already generated a wealth of clinical data on the benefits of remdesivir, providing much-needed hope to patients and healthcare providers worldwide. On the basis of this data, remdesivir has been approved or authorized for temporary use to treat COVID-19 in more than 50 countries worldwide. Today’s peer-reviewed data come from the gold standard randomized, double-blind, placebo-controlled Phase 3 study led by the U.S National Institute of Allergy and Infectious Diseases (NIAID). They provide new information that expands on the benefits of remdesivir and offer greater hope than ever in the fight against COVID-19.Continue reading
Hexoskin Reaches New Milestone for Scientific and Peer-reviewed Publications
AZBio Member, Hexoskin, has reached an important milestone. The company announced that the Hexoskin Connected Health Platform has been used in over 100 scientific & peer-reviewed publications thanks to our community of researchers and scientists dedicated to promoting safe and effective remote monitoring technologies.Continue reading
TGen Launches Vidium Animal Health
After more than a decade of studying naturally occurring cancer in pet dogs, the next logical step was developing a company to provide genomic-based precision-medicine to veterinary oncologists and pet parents. TGen did just that with the launch of Vidium Animal Health.Continue reading
Findings Reveal Hundreds of Mutated Genes Could Contribute to Cerebral Palsy: International Study Will Allow Physicians to Identify Genetic Cause of Cerebral Palsy for Many
A new study provides the first strong statistical and laboratory evidence that a large proportion of cerebral palsy cases are caused by mutations in a single gene. These findings will directly inform clinical care by improving physicians’ ability to identify the cause of an individual’s cerebral palsy, which will provide closure for families, guide preventative health care and can even alter the course of treatment.
Puritize®, a new UV-C Home Sanitizing System, Announces Results of SARS-CoV-2 Scientific Testing
Puritize®, the first scientifically proven, patented product available for home use for killing more than 99.9% of germs, bacteria and viruses, including SARS-CoV-2, on personal items, is now available to consumersContinue reading
ClōSYS CEO Jim Ratcliff Wins CEO Today USA Award
SCOTTSDALE, AZ (September 24, 2020) –– James (Jim) Ratcliff, Ph.D., Chairman and CEO of Rowpar Pharmaceuticals Inc., the makers of the ClōSYS brand of oral care products, has been named a 2020 CEO Today USA Award winner.Continue reading
Now Is Not The Time To Lift Mask Requirements
- Rolling back mask and distancing mandates now will reverse gains in slowing the spread
- AZBio PSA Reminds Arizonans to Make Good Choices and Mask Up
- Banner Health opposes lifting mask mandates
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.SContinue reading
Systems Oncology, an AI-based cancer therapy discovery and development company, is honored with a 2020 AZBio Fast Lane Award
Systems Oncology is using AI to Innovate Drug Discovery & DevelopmentContinue reading